- Direction
- Deteriorating
- Own history
- 70th
- Peers
- 51th
- Persistence
- EMERGING
· Surgical & Medical Instruments & Apparatus
RESEARCH SNAPSHOTWEST PHARMACEUTICAL SERVICES INC's latest supported as-filed period reports revenue of $874.5M; gross margin moved 315 basis points higher on the same comparison basis. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Separate current dimensions—not a universal score or investment ranking.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 23.20% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 4.47% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 21.67% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 8.69% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 53.14% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 39.73% · CORE
Level · gp.fundamentals.operating_margin
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 8.7%; Operating margin moved 975 bp higher; Operating income increased 59.5%.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Cash & equivalents decreased 14.5%; Operating cash flow decreased 30.0%.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Cash & equivalents decreased 26.2%; Operating cash flow decreased 3.9%.
2 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 13.8%; Operating margin moved 48 bp higher; Operating income increased 16.5%.
3 evidence-backed componentsOperating margin changed +975 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Each point keeps the date investors could first observe it and its accession.
WST · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0000105770-26-000121SEC ↗8-KOct 29, 2026Period Oct 29, 20260000105770-26-000118SEC ↗8-KOct 26, 2026Period Oct 26, 20260000105770-26-000114SEC ↗4Oct 2, 2026Period Sep 30, 20260000105770-26-000112SEC ↗4Sep 15, 2026Period Sep 11, 20260000105770-26-000110SEC ↗4Sep 10, 2026Period Sep 8, 20260000105770-26-000108SEC ↗4Sep 10, 2026Period Sep 8, 20260001518973-26-000007SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 30, 2026Filed Oct 2, 2026 | HAUGEN JANET BRUTSCHEADirector | Grant Or AwardDirect | 44 | $371 | $16,313 | Form 4 ↗ |
| Sep 8, 2026Filed Sep 10, 2026 | Lagarde MichelPresident and CEO | Grant Or AwardDirect | 13,879 | $0 | $0 | Form 4 ↗ |
| Sep 8, 2026Filed Sep 10, 2026 | Lagarde MichelPresident and CEO | Grant Or AwardDirect | 11,081 | $0 | $0 | Form 4 ↗ |
| Sep 8, 2026Filed Sep 10, 2026 | Lagarde MichelPresident and CEO | Grant Or AwardDirect | 12,088 | $0 | $0 | Form 4 ↗ |
| Sep 8, 2026Filed Sep 10, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 30.58% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 2.09% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 0.49% · OPTIONAL
Operating income changed +59.5% from the comparable as-filed period.
Operating cash flow changed -30.0% from the comparable as-filed period.
Gross margin changed +315 basis points from the comparable as-filed period.
Trade receivables changed +22.3% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Shares outstanding changed -3.2% from the comparable as-filed period. The change ranks at the 100th percentile of 8 prior comparable changes.
Trade receivables changed +19.7% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-09-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0000105770-26-000104| Lagarde MichelPresident and CEO |
| Grant Or AwardDirect |
| 6,200 |
| $0 |
| $0 |
| Form 4 ↗ |
| Sep 8, 2026Filed Sep 10, 2026 | Lagarde MichelPresident and CEO | Grant Or AwardDirect | 4,950 | $0 | $0 | Form 4 ↗ |
| Sep 8, 2026Filed Sep 10, 2026 | Lagarde MichelPresident and CEO | Grant Or AwardDirect | 3,600 | $0 | $0 | Form 4 ↗ |
| Aug 11, 2026Filed Aug 12, 2026 | McMahon Robert W.SVP & Chief Financial Officer | Option ExerciseDirect | 794.47 | — | — | Form 4 ↗ |
| Aug 11, 2026Filed Aug 12, 2026 | McMahon Robert W.SVP & Chief Financial Officer | Tax WithholdingDirect | 345.52 | $351 | $121,404 | Form 4 ↗ |
| Aug 11, 2026Filed Aug 12, 2026 | McMahon Robert W.SVP & Chief Financial Officer | Option ExerciseDirect | 6,354.74 | — | — | Form 4 ↗ |
| Aug 11, 2026Filed Aug 12, 2026 | McMahon Robert W.SVP & Chief Financial Officer | Tax WithholdingDirect | 2,763.68 | $351 | $971,072 | Form 4 ↗ |
| Aug 11, 2026Filed Aug 12, 2026 | McMahon Robert W.SVP & Chief Financial Officer | Option ExerciseDirect | 6,354.74 | $0 | $0 | Form 4 ↗ |
| Aug 11, 2026Filed Aug 12, 2026 | McMahon Robert W.SVP & Chief Financial Officer | Option ExerciseDirect | 794.47 | $0 | $0 | Form 4 ↗ |
| Jun 30, 2026Filed Jul 1, 2026 | HAUGEN JANET BRUTSCHEADirector | Grant Or AwardDirect | 46 | $359 | $16,514 | Form 4 ↗ |
| May 12, 2026Filed May 14, 2026 | Campbell Shane AldenSVP, Proprietary Segment | Option ExerciseDirect | 296 | — | — | Form 4 ↗ |
| May 12, 2026Filed May 14, 2026 | Campbell Shane AldenSVP, Proprietary Segment | Tax WithholdingDirect | 84.33 | $312 | $26,317 | Form 4 ↗ |
| May 12, 2026Filed May 14, 2026 | Campbell Shane AldenSVP, Proprietary Segment | Option ExerciseDirect | 473.59 | — | — | Form 4 ↗ |
| May 12, 2026Filed May 14, 2026 | Campbell Shane AldenSVP, Proprietary Segment | Tax WithholdingDirect | 134.93 | $312 | $42,107 | Form 4 ↗ |
| May 12, 2026Filed May 14, 2026 | Campbell Shane AldenSVP, Proprietary Segment | Option ExerciseDirect | 296 | $0 | $0 | Form 4 ↗ |
| May 12, 2026Filed May 14, 2026 | Campbell Shane AldenSVP, Proprietary Segment | Option ExerciseDirect | 473.59 | $0 | $0 | Form 4 ↗ |